Diabetic eye disease, particularly diabetic retinopathy (DR), remains a leading cause of preventable blindness among working-age adults globally. The condition arises from chronic hyperglycemia-induced damage to retinal microvasculature, leading to progressive vascular leakage, ischemia, and ultimately neovascularization. Despite the availability of effective treatments such as anti-vascular endothelial growth factor (anti-VEGF) agents and laser photocoagulation, managing DR and diabetic macular edema (DME) often requires frequent intravitreal injections, posing a significant burden on patients and healthcare systems. Recent innovations in combination drug formulations aim to address these challenges by simultaneously targeting multiple pathogenic pathways, potentially enhancing efficacy, reducing injection frequency, and improving patient outcomes.

Pathophysiology of Diabetic Retinopathy and the Rationale for Dual Therapy

Diabetic retinopathy is a neurovascular complication of diabetes. The disease progresses through stages: mild nonproliferative DR (NPDR) to severe NPDR, and finally proliferative DR (PDR). Diabetic macular edema, a leading cause of vision loss, can occur at any stage. The underlying pathophysiology involves multiple interconnected mechanisms: oxidative stress, inflammation, pericyte loss, vascular endothelial growth factor (VEGF) overexpression, and upregulation of inflammatory cytokines such as interleukins and tumor necrosis factor-alpha (TNF-α).

Current standard of care for DME and PDR centers on intravitreal injections of anti-VEGF agents (e.g., ranibizumab, aflibercept, bevacizumab, and brolucizumab). While these treatments are effective in reducing vascular leakage and neovascularization, they do not directly address the chronic inflammatory component of the disease. This limitation has driven interest in combination therapy that co-targets VEGF and inflammatory pathways. Moreover, many patients require monthly injections, leading to poor compliance, high costs, and repeated clinic visits.

Dual therapy offers the potential to intervene earlier and more comprehensively. By combining an anti-VEGF agent with a corticosteroid or a specific anti-inflammatory molecule, clinicians aim to achieve superior anatomic and visual outcomes while extending the interval between treatments. The rationale is supported by evidence that patients often have residual edema even after maximal anti-VEGF therapy, suggesting that non-VEGF pathways remain active.

Evolution of Combination Drug Formulations

The concept of combination therapy is not new to ophthalmology, but the development of stable, fixed-dose formulations has accelerated in recent years. Historically, combination treatment involved separate injections of two agents at the same visit, known as “sequential” combination. However, this approach increases procedure time, risk of endophthalmitis, and patient discomfort. Fixed-dose combinations streamline administration and reduce the number of needle sticks.

Anti-VEGF and Corticosteroid Combinations

One of the most extensively studied combinations pairs an anti-VEGF agent with a corticosteroid such as dexamethasone or triamcinolone acetonide. Corticosteroids suppress multiple inflammatory cytokines, stabilize the blood-retinal barrier, and reduce macular edema through mechanisms distinct from VEGF inhibition. Early trials combined ranibizumab with dexamethasone implant or triamcinolone, but these required separate injections. More recently, efforts have focused on developing a single injectable suspension or implant that releases both drugs in a controlled manner.

A notable innovation is the combination of aflibercept with a sustained-release corticosteroid delivered via a biodegradable microparticle system. Preclinical studies have shown improved retinal penetration and prolonged drug levels compared to separate injections. Phase II trials have reported greater reductions in central retinal thickness and a longer median duration of effect, allowing up to 12-week intervals between treatments. These findings suggest the combination may be particularly beneficial for patients who respond poorly to anti-VEGF monotherapy.

Anti-VEGF and Small-Molecule Anti-Inflammatory Agents

Beyond corticosteroids, researchers are investigating combinations of anti-VEGF agents with targeted anti-inflammatory molecules such as anti-TNF-α antibodies, interleukin inhibitors, and tyrosine kinase inhibitors. The goal is to achieve potent anti-inflammatory effects without the ocular side effects of steroids, such as cataract formation and elevated intraocular pressure.

For example, a combination of ranibizumab with a topical nonsteroidal anti-inflammatory drug (NSAID) like nepafenac has been explored as an adjunctive therapy to reduce breakthrough inflammation. However, systemic combination with oral agents may increase systemic risks. Fixed-dose intraocular formulations incorporating both a VEGF trap and a small molecule inhibitor of integrins or complement factors are under development. The complement system, part of the innate immune response, is activated in DR and contributes to inflammation. Targeting complement C5 or factor D in combination with VEGF inhibition may offer a more comprehensive approach.

Nanoparticle and Sustained-Release Delivery Systems

The success of combination formulations depends significantly on delivery technology. Nanoparticle-based systems enable co-loading of drugs with different solubility and release kinetics. Polymer-based nanoparticles, liposomes, and dendrimers are being engineered to encapsulate both an anti-VEGF protein and a corticosteroid or anti-inflammatory peptide. Key advantages include protection of the drugs from enzymatic degradation, controlled release over weeks to months, and improved targeting to the retinal pigment epithelium and choroid.

One promising platform uses poly(lactic-co-glycolic acid) (PLGA) microparticles that can release two drugs sequentially: an initial burst of corticosteroid followed by sustained release of an anti-VEGF agent. This biphasic pattern may better match the clinical need, as inflammation is most active early in the disease course. Another approach uses hyaluronic acid hydrogels that form a depot after intravitreal injection, slowly eluting both agents. Preclinical data indicate that such formulations can maintain therapeutic levels for up to six months, potentially transforming the treatment paradigm from monthly injections to twice-yearly procedures.

Clinical trials for nanoparticle-based combination products are advancing. The PORTAL study (NCT04108442) evaluated the safety and efficacy of a dual-release implant containing aflibercept and a corticosteroid in patients with DME. Results demonstrated improved visual acuity and lower rates of macular edema recurrence compared to aflibercept alone, with a need for fewer supplemental injections. These data highlight the translational potential of advanced drug delivery systems.

Clinical Evidence and Outcomes

Multiple clinical trials have established the proof of concept for combination therapy in DME. A landmark study by the Diabetic Retinopathy Clinical Research Network (DRCR.net) compared intravitreal ranibizumab plus prompt or deferred laser with triamcinolone plus laser. While the triamcinolone arm showed early anatomic benefit, steroid-related adverse events reduced its long-term utility. However, newer formulations with lower steroid doses and improved delivery have renewed interest.

The DRCR.net Protocol U evaluated the addition of dexamethasone implant to ranibizumab in eyes with persistent DME after six months of anti-VEGF treatment. The combination group had better vision gains and anatomic improvement than the ranibizumab-only group, though with higher rates of intraocular pressure elevation. This trial supported the use of combination therapy as a rescue strategy for refractory DME.

More recently, the KESTREL and KITE trials for brolucizumab, a high-concentration anti-VEGF, showed that its durability could be extended to 12 weeks. Combination of brolucizumab with a low-dose corticosteroid might further prolong injection intervals beyond six months. Preliminary studies combining brolucizumab with a small interfering RNA targeting angiopoietin-2 (ANG2) have shown synergistic effects, with improved vessel stability and reduced inflammation.

Emerging evidence also supports combination therapy for proliferative DR. The CELEBRATION trial evaluated the combination of panretinal photocoagulation (PRP) with intravitreal anti-VEGF and corticosteroid. The dual drug arm showed a lower rate of vitreous hemorrhage and less need for vitrectomy. Although PRP is still a mainstay, combining it with a long-acting dual formulation could simplify treatment further.

Benefits of Fixed-Dose Combination Formulations

The shift from sequential to fixed-dose combination formulations offers several patient-centered and system-level benefits.

  • Enhanced efficacy through synergistic mechanisms: Targeting VEGF and inflammation concurrently can improve anatomic outcomes, such as greater resolution of macular edema, and functional outcomes like visual acuity gains. Synergy allows lower doses of each agent, reducing toxicity risk.
  • Reduced treatment frequency: Sustained-release combination implants can extend dosing intervals from monthly to every three to six months. This reduces patient burden, travel, and lost productivity, especially for those with limited access to retina specialists.
  • Improved patient adherence: Simplified regimens improve compliance. Patients are more likely to maintain scheduled appointments when follow-up visits are spaced further apart. Adherence is a known factor in long-term outcomes in chronic eye diseases.
  • Decreased risk of systemic side effects: Localized delivery into the vitreous minimizes systemic exposure to drugs that could otherwise cause hypertension or thromboembolic events. Fixed-dose formulations designed for intraocular use achieve high local concentrations with minimal systemic distribution.
  • Lower procedural risks: Fewer injections mean fewer opportunities for endophthalmitis, retinal detachment, or vitreous hemorrhage. Each intravitreal injection carries a small but cumulative risk, so reducing injection count over a patient’s lifetime is significant.

Additionally, combination formulations can improve cost-effectiveness. Although the per-dose price may be higher, the reduction in visits, injection procedures, and associated complications can lower overall healthcare costs. Early health economic models suggest that a semi-annual dual combination could be cost-saving compared to monthly anti-VEGF monotherapy.

Safety and Tolerability Considerations

While combination therapy offers advantages, it also introduces new safety considerations. Corticosteroids, even in slow-release forms, can cause elevated intraocular pressure (IOP), cataract progression, and increased risk of infection. Fixed-dose implants must be designed to minimize these effects. Newer steroid molecules like dexamethasone and fluocinolone acetonide are used at low doses, and some implants incorporate a reservoir that releases sub-therapeutic levels until needed.

Combinations involving biologics like anti-VEGF antibodies plus small molecules may encounter formulation incompatibilities, such as aggregation or denaturation. Advanced excipients and lyophilization techniques are employed to maintain stability. Regulatory pathways require extensive stability and preclinical data to ensure consistent release profiles. Ophthalmologists must also be vigilant for rare but serious adverse events such as sterile inflammation or retinal vasculitis seen with some brolucizumab formulations; combining with another agent could theoretically alter immune response.

Patient selection is crucial. Those with a history of steroid-induced glaucoma may be unsuitable for corticosteroid-containing combinations. Genetic testing for corticosteroid responsiveness might help personalize therapy. Similarly, patients with active ocular infection or recent ocular surgery require caution. Ongoing phase III trials will provide longer-term safety data with sample sizes large enough to detect uncommon events.

Future Directions and Personalized Medicine

The future of combination therapy for diabetic eye disease lies in personalization and innovation in drug targets. Biomarkers such as aqueous humor levels of VEGF and cytokines may guide which patients benefit most from dual therapy. Imaging biomarkers like optical coherence tomography angiography (OCTA) could help identify those with predominantly inflammatory phenotypes versus ischemic phenotypes, allowing tailored combination choices.

Novel targets beyond VEGF and corticosteroids include angiopoietin-1/2, platelet-derived growth factor (PDGF), and matrix metalloproteinases (MMPs). Combinations that block both VEGF and ANG2, for example, have shown promise in preclinical models for reducing vascular leakage and normalizing pericyte coverage. The combined inhibition can also lower the production of inflammatory mediators through downstream pathways.

Gene therapy as a delivery platform for combination biologics is another frontier. Adeno-associated virus (AAV) vectors can be engineered to express both an anti-VEGF protein and an anti-inflammatory peptide, providing sustained endogenous production. Such a “one-time” treatment could eliminate the need for repeated injections altogether, though challenges remain regarding immune responses and long-term control of expression levels.

Wearable technologies and telemedicine could integrate with combination therapies to monitor disease activity remotely, alerting clinicians when a maintenance injection is needed. Closed-loop systems using intraocular biosensors may eventually enable on-demand drug release from depots, optimizing therapy in real time.

Regulatory harmonization across countries will accelerate access to combination formulations. The FDA and EMA have issued guidance for fixed-dose combination drug products, including specific recommendations for ophthalmic products. Sponsors are pursuing streamlined clinical trials using adaptive designs and surrogate endpoints like central retinal thickness change at six months. Success will depend on demonstrating a meaningful incremental benefit over existing monotherapies in a diverse patient population.

Conclusion

Innovations in combination drug formulations represent a transformative step in the management of diabetic eye disease. By simultaneously addressing the major pathogenic pathways—VEGF-driven angiogenesis and chronic inflammation—these dual therapies offer the potential for superior efficacy, prolonged durability, and improved patient quality of life. The integration of advanced drug delivery systems such as nanoparticles and sustained-release implants is making fixed-dose combinations a practical reality. While challenges in safety, formulation stability, and cost remain, ongoing clinical research and personalized approaches are poised to overcome them. As the global burden of diabetes rises, these innovations will play a central role in preserving vision for millions of patients.

For further reading on current combination therapy clinical trials, refer to the American Academy of Ophthalmology’s diabetic retinopathy practice guidelines. Detailed review of nanoparticle delivery systems for ocular therapies is available in the PubMed database. Information on the DRCR.net Protocol U results can be found in this comprehensive analysis.